science.bio dihexa | | 1401708-83-5 DIHEXA | Peptide Synthetic |

The mechanisms sustaining this heterogeneity are unknown, although it should be acknowledged that CVOTs lack the statistical power to reliably detect differences in specific MACE components

Because of BPC-157s original gastric source, the oral version (as a mouth spray) is being used for GERD, stomach ulcers, Crohns disease, ulcerative colitis and leaky gut

It is also one of the three actives in the Peptual transdermal patch he endorses, alongside BPC-157 and NAD+: BPC-157: ~2000 mcg NAD+: ~250 mg GHK-Cu: ~10 mg The patch combines tissue repair (BPC-157), cellular energy (NAD+), and collagen synthesis (GHK-Cu) in a sustained-release format (source)

What to Expect Over Time Weeks 12: Decrease in inflammation and discomfort Early improvements in digestion and gut comfort (oral form) Weeks 36: Improved tissue repair and mobility Enhanced recovery and energy levels Weeks 612+: Long-term improvements in joint, tendon, and muscle strength Sustained gut health and systemic support Results vary depending on condition, severity, and consistency of use